0
0

Immunohematology Tests – Medical Devices Pipeline Assessment, 2020

Immunohematology Tests includes studies of antigen-antibody reactions and analogous phenomena as they relate to the pathogenesis and clinical manifestations of blood disorders. This category includes blood typing reagents and antibody detection reagents. GlobalData's Medical Devices sector report, “Immunohematology Tests – Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Immunohematology Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Immunohematology Tests Pipeline Assessment report provides key information and data related to:

Extensive coverage of the Immunohematology Tests under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Immunohematology Tests pipeline products.

Review of Recent Developments in the segment / industry

The Immunohematology Tests Pipeline Assessment report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Drainage Device sunder development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

The major companies covered in the “Immunohematology Tests- Medical Devices Pipeline Assessment, 2020” report:

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

Extensive coverage of the Immunohematology Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Immunohematology Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to:

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Immunohematology Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product’s current stage of development, territory and estimated launch date

Companies mentioned

AbSorber AB

Alba Bioscience Limited

Amity University

Biofortuna Ltd

Calviri Inc

Grifols SA

Ortho-Clinical Diagnostics Inc

Quotient Ltd

SiDx Inc

Transfusion & Transplantation Technologies (Inactive)

Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Immunohematology Overview 6

3 Products under Development 7

3.1 Immunohematology – Pipeline Products by Stage of Development 7

3.2 Immunohematology – Pipeline Products by Segment 8

3.3 Immunohematology – Pipeline Products by Territory 9

3.4 Immunohematology – Pipeline Products by Regulatory Path 10

3.5 Immunohematology – Pipeline Products by Estimated Approval Date 11

4 Immunohematology – Pipeline Products under Development by Companies 12

4.1 Immunohematology Companies – Pipeline Products by Stage of Development 12

4.2 Immunohematology – Pipeline Products by Stage of Development 13

5 Immunohematology Companies and Product Overview 14

5.1 AbSorber AB Company Overview 14

5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 14

5.2 Alba Bioscience Limited Company Overview 15

5.2.1 Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 15

5.3 Amity University Company Overview 17

5.3.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 17

5.4 Biofortuna Ltd Company Overview 18

5.4.1 Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 18

5.5 Calviri Inc Company Overview 24

5.5.1 Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 24

5.6 Grifols SA Company Overview 25

5.6.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 25

5.7 Ortho-Clinical Diagnostics Inc Company Overview 26

5.7.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 26

5.8 Quotient Ltd Company Overview 28

5.8.1 Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

5.9 SiDx Inc Company Overview 32

5.9.1 SiDx Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.10 Transfusion & Transplantation Technologies (Inactive) Company Overview 33

5.10.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

6 Immunohematology- Recent Developments 38

6.1 Aug 11, 2020: Bio-Techne announces release of a new sars-cov-1/2 spike rbd llamabody recombinant antibody that blocks viral entry 38

6.2 Jul 30, 2020: LabCorp working with public health authorities on no-charge antibody test program to accelerate COVID-19 blood plasma donation 38

6.3 Jul 01, 2020: Nanommune partners With Velox Biosystems to offer laboratory testing of COVID-19 serological assays 39

6.4 Jun 09, 2020: Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities 39

6.5 May 13, 2020: Creoptix collaborates with Prof. Adriano Aguzzi and the University of Zurich to characterize anti-SARS-CoV-2 antibodies in patients with coronavirus 40

6.6 Apr 21, 2020: AvantGen announces the rapid identification and promising initial testing of antibodies intended to diagnose SARS-CoV-2 infection and treat COVID-19 40

6.7 Feb 27, 2020: Grifols reaches revenue of EUR 5,100 million, a

13.6% increase, and raises its profits to EUR 625 million 41

6.8 Feb 13, 2020: Bio-Rad reports fourth-quarter and full-year 2019 financial results 47

6.9 Feb 04, 2020: Bio-Rad brings FCS express flow cytometry analysis software to ZE5 cell analyzer users 49

6.10 Feb 03, 2020: Siemens Healthineers starts new fiscal year with strong growth – outlook confirmed 50

6.11 Jan 30, 2020: Quotient provides an update on recent MosaiQ milestone achievements together with third quarter fiscal 2020 results 52

6.12 Jan 30, 2020: Theradiag reports 2019 revenue of €9.6 million, Up

8.3% 54

6.13 Jan 07, 2020: Quotient announces appointment of new chief financial officer Peter Buhler and chief operating officer Ed Farrell 55

6.14 Jan 06, 2020: Bio-Rad appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President 56

6.15 Dec 23, 2019: The International Trade Commission issues final decision affirming 10X Genomics infringement of three of Bio-Rad’s Patents 56

6.16 Dec 13, 2019: Bio-Rad makes progress recovering from recent ransomware attack 57

6.17 Dec 11, 2019: Haemonetics opens new corporate headquarters in Downtown Boston 57

6.18 Dec 10, 2019: Siemens Healthineers gives details on second phase of Strategy 2025 and on the further development of its businesses 58

7 Appendix 60

7.1 Methodology 60

7.2 About GlobalData 64

7.3 Contact Us 64

List of Tables

Table 1: Immunohematology – Pipeline Products by Stage of Development 7

Table 2: Immunohematology – Pipeline Products by Segment 8

Table 3: Immunohematology – Pipeline Products by Territory 9

Table 4: Immunohematology – Pipeline Products by Regulatory Path 10

Table 5: Immunohematology – Pipeline Products by Estimated Approval Date 11

Table 6: Immunohematology Companies – Pipeline Products by Stage of Development 12

Table 7: Immunohematology – Pipeline Products by Stage of Development 13

Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 14

Table 9: ABO Diagnostic Test – Product Status 14

Table 10: ABO Diagnostic Test – Product Description 14

Table 11: Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 15

Table 12: ALBAcyte O Adult i Cell Reagent – Product Status 15

Table 13: ALBAcyte O Adult i Cell Reagent – Product Description 15

Table 14: ALBAcyte O RhD VI Reagent Cells – Product Status 15

Table 15: ALBAcyte O RhD VI Reagent Cells – Product Description 16

Table 16: Amity University Pipeline Products & Ongoing Clinical Trials Overview 17

Table 17: Blood Group Testing Kit – Product Status 17

Table 18: Blood Group Testing Kit – Product Description 17

Table 19: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 18

Table 20: HemoPlex Kell Genotyping Kit – Product Status 18

Table 21: HemoPlex Kell Genotyping Kit – Product Description 18

Table 22: HemoPlex Kidd & Duffy Genotyping Kit – Product Status 19

Table 23: HemoPlex Kidd & Duffy Genotyping Kit – Product Description 19

Table 24: HemoPlex MNS Genotyping Kit – Product Status 19

Table 25: HemoPlex MNS Genotyping Kit – Product Description 19

Table 26: HemoPlex Multi Blood Group Genotyping Kit – Product Status 20

Table 27: HemoPlex Multi Blood Group Genotyping Kit – Product Description 20

Table 28: HemoPlex RHCE Screening Kit – Product Status 20

Table 29: HemoPlex RHCE Screening Kit – Product Description 20

Table 30: HemoPlex RHCE Variant Genotyping Kit – Product Status 21

Table 31: HemoPlex RHCE Variant Genotyping Kit – Product Description 21

Table 32: HemoPlex RHD & CE Genotyping Kit – Product Status 21

Table 33: HemoPlex RHD & CE Genotyping Kit – Product Description 21

Table 34: HemoPlex RHD Variant Genotyping Kit – Product Status 22

Table 35: HemoPlex RHD Variant Genotyping Kit – Product Description 22

Table 36: ThromboPlex HPA Screening Kit – Product Status 22

Table 37: ThromboPlex HPA Screening Kit – Product Description 23

Table 38: Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 39: Blood Screening Immunosignaturing – Product Status 24

Table 40: Blood Screening Immunosignaturing – Product Description 24

Table 41: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 25

Table 42: IH Blood Genotyping (D) Kit – Product Status 25

Table 43: IH Blood Genotyping (D) Kit – Product Description 25

Table 44: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 45: ORTHO AutoVue – Rare Sera Assay – Product Status 26

Table 46: ORTHO AutoVue – Rare Sera Assay – Product Description 26

Table 47: ORTHO BioVue – Rare Sera Assay – Product Status 27

Table 48: ORTHO BioVue – Rare Sera Assay – Product Description 27

Table 49: Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

Table 50: Eluate Kit – Product Status 28

Table 51: Eluate Kit – Product Description 28

Table 52: Expanded IH Microarray – Product Status 29

Table 53: Expanded IH Microarray – Product Description 29

Table 54: IH Microarray Patient – Product Status 29

Table 55: IH Microarray Patient – Product Description 30

Table 56: Polyagglutionation Kit – Product Status 30

Table 57: Polyagglutionation Kit – Product Description 30

Table 58: Sensitivity Kit Anti-S, K, e, C – Product Status 30

Table 59: Sensitivity Kit Anti-S, K, e, C – Product Description 31

Table 60: SiDx Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 61: Blood Group Testing Chip – Product Status 32

Table 62: Blood Group Testing Chip – Product Description 32

Table 63: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

Table 64: Aegis – Anti-A Quantitation In Group O Platelets – Product Status 33

Table 65: Aegis – Anti-A Quantitation In Group O Platelets – Product Description 33

Table 66: Aegis – Antibody Screening And Identification Assay – Product Status 34

Table 67: Aegis – Antibody Screening And Identification Assay – Product Description 34

Table 68: Aegis – Blood Grouping Assay – Product Status 34

Table 69: Aegis – Blood Grouping Assay – Product Description 35

Table 70: Aegis – Platelet Cross-match Assay – Product Status 35

Table 71: Aegis – Platelet Cross-match Assay – Product Description 35

Table 72: Aegis – Residual A Quantitation Assay – Product Status 36

Table 73: Aegis – Residual A Quantitation Assay – Product Description 36

Table 74: Aegis – rWBC Quantitation Assay – Product Status 36

Table 75: Aegis – rWBC Quantitation Assay – Product Description 37

Table 76: AEGIS System – Product Status 37

Table 77: AEGIS System – Product Description 37

List of Figures

Figure 1: Immunohematology – Pipeline Products by Stage of Development 7

Figure 2: Immunohematology – Pipeline Products by Segment 8

Figure 3: Immunohematology – Pipeline Products by Territory 9

Figure 4: Immunohematology – Pipeline Products by Regulatory Path 10

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports

© GlobalData UK Ltd, a company registered in England and Wales, with company number 05968121 and registered address John Carpenter House, John Carpenter Street, London EC4Y 0AN. GlobalData UK Ltd is a wholly owned subsidiary of GlobalData PLC, with company number 03925319